Catabasis shares 1st triglyceride data for drug conjugate
This article was originally published in Scrip
Executive Summary
Preliminary data from a Phase I clinical trial for the Catabasis Pharmaceuticals hypertriglyceridemia drug CAT-2003 show significant reductions in fasting and post-prandial triglyceride levels in both healthy volunteers and patients with mild lipid elevations.